US tariffs on pharmaceutical imports will affect India’s pharma sector, a leader in affordable generics. Analyst Vishal Manchanda highlights risks to Indian firms like Sun Pharma and Cipla due to pricing pressures, but anticipates growth in domestic and emerging markets.
